omniture

China Medicine's ADTZ Product Highlighted at the Recent American Chemical Society's 233rd National Meeting

China Medicine Corporation
2007-04-09 21:08 696


GUANGZHOU, China, April 9 /Xinhua-PRNewswire-FirstCall/ -- China Medicine Corporation (OTC Bulletin Board: CHME), a leading distributor of medical products, traditional pharmaceutical and Chinese medicines, herbs and dietary supplements announced today that the Company's proprietary ADTZ product was discussed as a viable means to reduce aflatoxins in the creation of ethanol based products from corn feed at the recent American Chemical Society, 233rd National Meeting Agricultural Biomass, Biobased Products, & Biofuels Symposium, which was held in Chicago, Illinois on March 25th through the 29th.

Dr Jiujiang Yu, Research Geneticist from the United States Department of Agriculture (USDA) presented his findings at the conference in regards to the presence of aflatoxins in corn feed and its implications in biofuel conversion from corn to ethanol. Aflatoxins have been known to be toxic and potent cancer inducing compounds. Aflatoxin contaminated corn can not be used for food and feed purposes, but can be used for ethanol production. However, aflatoxins could also be detrimental in fermentation and their potential hazard to health and to the environment when ethanol is used, as fuel is unclear. Future research may indicate it is necessary to remove or reduce aflatoxin levels in corn for use in ethanol production. Dr. Yu mentioned that the gene encoding for ADTZ enzyme can be engineered into fermentation organism used for ethanol production and hence aflatoxins could be effectively detoxified in the process.

CO-WIN Bioengineering is a majority owned subsidiary of China Medicine Corporation and has been working closely on the ADTZ solution to remove aflatoxins from a variety of different foods and animal feed. Dr.Yao from CO-WIN Bioengineering is spearheading the Company's efforts and has more than 13 years of expertise in this field. Dr. Yao previous positions included Professor of Jinan University, the President of the Institute of Microbial Biotechnology, Jinan University and he also served as a member of Chinese Society for Enzyme Engineering. As a result of this work, China Medicine has 6 patents pending related to this proprietary product.

"China Medicine is committed to creating a commercialized product platform that can remove the presence of dangerous aflatoxins from commonly used products," commented Mr. Yang, CEO of China Medicine. "We have been jointly working on our ADTZ product with Dr. Yao for 3 years and have committed significant resources towards improving efficacy while receiving the necessary approvals. As a result we expect our product to reach the commercialization stage by late 2007."

About China Medicine Corporation

China Medicine is a distributor of medical products, traditional pharmaceutical medicines, traditional Chinese medicines, Chinese herbs and dietary supplements to over 28 provinces and 2,500 customers within China. The Company sells more than 1,100 products and is actively building a pipeline of proprietary traditional and Chinese herbal remedy products targeting oncology, high blood pressure and the removal of Aflatoxins from food and animal feed. For more information visit the Company's website at http://www.chinamedicinecorp.com .

Safe Harbor Statement

This press release contains forward-looking statements concerning China Medicine Corporation's business and products. The actual results may differ materially depending on a number of risk factors including, but not limited to, the following: general economic and business conditions, development, shipment, market acceptance, additional competition from existing and new competitors, changes in technology, and various other factors beyond its control. All forward-looking statements are expressly qualified in their entirety by this Cautionary Statement and the risks factors detailed in the Company's reports filed with the Securities and Exchange Commission. China Medicine Corporation undertakes no duty to revise or update any forward- looking statements to reflect events or circumstances after the date of this release

For more information, please contact:

Company Contact:

Mary Xia, China Medicine Corporation

Tel: +1-732-438-8866

Email: mary66882002@yahoo.com

Investor Contact:

Matt Hayden, Hayden Communications

Tel: +1-858-704-5065

Email: matt@haydenir.com

Source: China Medicine Corporation
collection